1. Power THE FUTURE OF FIGHTING CANCER
How to increase cancer cure rate by 30% by 2030
Power
SDS Optic Inc.
Lublin, Poland
Presentation Template

2. Almost 9 million people die each year from cancer
There are more than 100 types of cancers – most defined by tumor biology & cancer biomarkers
Almost 9 million people die each year from cancer
70% - the increase in new cases of cancer expected over the next 2 decades
* Source: World Health Organization

3. FACTS & CHALLANGES The Future of cancer treatment is here …
Targeted-Immune-Gene-Cell/CAR-T Therapies
2 milion new cases of Breast Cancer in 2018, 0.5 milion deaths. Major reason – LATE or FALSE diagnosis and no treatment monitoring technologies
Real-Time in vivo & no false targeted tumor biology diagnostics is KEY
Average age of Pathologists in Europe has just exceeded 60 years, with very few young annual additions

4. Designed & Developed in Poland €9M raised to date
WHERE TARGET THERAPIES MEET TARGET DIAGNOSTICS
Invented in the U.S.
Designed & Developed in Poland
€9M raised to date

5. Disruptive 6-micron opto-biological Platform Technology
Merging fiber optics, biotech and engineering
Single-cell resolution Microprobe
Challenging the Paradigm
HER2 tumor biomarker in breast cancers as first in-human clinical application

6. Key Benefits in cancer diagnosis
In-vivo examination and real time results
No tissue biopsy. Results in mins
High Sensitivity
No tumor infraction. Enough to get close to the tumor with USG guidance
Objective results
Numerical results. No more FALSE POSITIVE or FALSE NEGATIVE results
Patients wellbeing
No waiting time. Immediate personalized targeted treatment introduction
Numerous scale-up possibilities
Most cancer biomarkers, real-time treatment monitoring

7. HER2+ Cancers Clinical Challenges – where we can help?
Cancer Biomarker Diagnosis
Identify Right Patients
Introduce effective innovative treatment
Drug delivery in SITU monitoring
Drug Success Rate & Patients Survival Rate
Visual examination
False -/+ results
WHO will benefit from specific targeted treatment ?
Has DRUG been delivered to the tumor area ?
Inject less or more?
Increase cancer complete remissions by 30% by 2030

8. Disruptive platform technology with wide scale-up opportunites

10. How we get here

11. Our Assets

12. Who Trusted Us

13. Thank you SDS Optic Inc. Konstantynow 1F 20-708 Lublin, POLAND
Follow us: